MBX Biosciences, Inc. Common Stock
MBX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.99B
Close$
$2.05
96.7% downside
Current Fair Value
96.7% downsideOvervalued by 96.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.99 Billion |
|---|---|
| Enterprise Value | $2.94 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.38 |
| Beta | 0.1 |
| Outstanding Shares | 47,696,363 |
Return
| Return on Equity | -25.47% |
|---|---|
| Return on Assets | -23.93% |
| Return on Invested Capital | -29.16% |
Valuation & Multiples
| P/E Ratio | -26.21 |
|---|---|
| PEG | -28.77 |
| Price to Sales | - |
| Price to Book Ratio | 7.75 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -24.48 |
| Enterprise Value to Net Income | -29 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.63
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.83
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6625▲ 27.90% |
|---|---|
| Total Calls | 354,400▲ 188.60% |
| Total Puts | 234,800▲ 398.51% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.81%▲ 4.01% |
|---|---|
| Total Invested | $3.07B▲ 96.08% |
| Investors Holding | 182▲ 21.00% |
ESG Score
No data
About MBX Biosciences, Inc. Common Stock
43 employees
CEO: Mr. Peter Kent Hawryluk MBA MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a ...